New study tracks mylotarg safety in AML patients

NCT ID NCT05189639

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is monitoring the safety and effects of Mylotarg in 165 adults in Korea who are newly diagnosed with acute myeloid leukemia (AML). Participants will receive Mylotarg as part of their routine care, and researchers will track any side effects and how the disease responds. The goal is to better understand the drug's safety and effectiveness in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mylotarg (gemtuzumab ozogamicin)
What this could lead to: If successful, this study could confirm that Mylotarg is a safe and effective treatment option for adults with newly diagnosed acute myeloid leukemia.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Side effects like serious infections are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Seoul national university hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.